We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Gold Nanoparticle-Based Test Better for Prostate Cancer Diagnosis Than PSA

By LabMedica International staff writers
Posted on 13 Apr 2015
Print article
Image: Illustration of the NanoDLSay light scattering assay for detecting target analytes by measuring nanoparticle size change (Photo courtesy of Nano Discovery Inc.).
Image: Illustration of the NanoDLSay light scattering assay for detecting target analytes by measuring nanoparticle size change (Photo courtesy of Nano Discovery Inc.).
A rapid and simple gold nanoparticle-based blood test proved better at diagnosing prostate cancer than did the commonly used PSA (prostate-specific antigen) assay.

Investigators at the University of Central Florida (Orlando, USA) based their NanoDLSay test on the ability of gold nanoparticles to bind certain proteins from the serum and to increase in size and change their light scattering properties.

When citrate ligands-capped gold nanoparticles are mixed with blood sera, a protein corona is formed on the nanoparticle surface due to the adsorption of various proteins in the blood to the nanoparticles. Using a two-step gold nanoparticle-enabled dynamic light scattering assay, the investigators discovered that the amount of human immunoglobulin G (IgG) in the gold nanoparticle protein corona was increased in prostate cancer patients compared to healthy controls. Two pilot studies conducted on blood serum samples collected at Florida Hospital (USA) and obtained from the Prostate Cancer Biorespository Network revealed that the test had 90%–95% specificity and 50% sensitivity in detecting early stage prostate cancer, representing a significant improvement over the current PSA test.

The investigators postulated that the increased amount of human IgG found in the protein corona was associated with the autoantibodies produced in cancer patients as part of the immune system's defense against the tumor. Proteomic analysis of the nanoparticle protein corona revealed molecular profile differences between serum samples from cancer patients and healthy individuals. Autoantibodies and natural antibodies produced in cancer patients in response to tumorigenesis have been found and detected in the blood of many cancer types. Thus, the test may be applicable for early detection and risk assessment of a broad spectrum of cancer types.

"What is different and unique about our technique is it is a very simple process, and the material required for the test is less than one USD," said senior author Dr. Qun Huo, professor of chemistry at the University of Central Florida. "And because it is low-cost, we are hoping most people can have this test in their doctor's office. If we can catch this cancer in its early stages, the impact is going to be big."

The investigators have founded the biomedical company Nano Discovery Inc. (Orlando, FL, USA) to commercialize the NanoDLSay diagnostic test for prostate cancer.

The report was published in the March 10, 2015, online edition of the journal ACS Applied Materials & Interfaces.

Related Links:
University of Central Florida
Nano Discovery Inc.


Gold Supplier
Anti-SARS-CoV-2 Controls Kit
ACCURUN Anti-SARS-CoV-2 Controls Kit
New
BCID Panels
ePlex Blood Culture Identification Panels
New
Fecal Calprotectin Testing Reagent
OC-FCa Reagent
New
Thrombosis Viscoelasic Analysis System
ImproClot

Print article

Channels

Molecular Diagnostics

view channel
Image: Researchers have identified the origin of subset of autoantibodies that worsen lupus (Photo courtesy of Pexels)

Lupus Biomarker Testing Could Help Identify Patients That Need Early and Aggressive Treatment

Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs when the body's antibodies, which usually protect against infections, attack healthy cells and proteins. These autoantibodies can... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Microbiology

view channel
Image: Use of DBS samples can break barriers in hepatitis C diagnosis and treatment for populations at risk (Photo courtesy of Pexels)

DBS-Based Assay Effective in Hepatitis C Diagnosis and Treatment for At Risk Populations

In a bid to eliminate viral hepatitis as a public health threat by 2030, the World Health Organization (WHO) has put forth a proposed strategy. To this end, researchers at the Germans Trias i Pujol Research... Read more

Pathology

view channel
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)

AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time

Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses... Read more

Technology

view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more

Industry

view channel
Image: The global antimicrobial resistance diagnostics market size is expected to reach USD 5.7 billion by 2028 (Photo courtesy of Pexels)

Global Antimicrobial Resistance Diagnostics Market Driven by Increasing Hospital-Acquired Infections

Antimicrobial drugs are intended to counteract the harmful effects of microbes and promote a healthy life. However, their excessive use can result in the development of resistance, commonly referred to... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.